Section H Update for Hospital Pharmaceuticals
Effective 1 November 2017
Cumulative for August, September, October and November 2017
Contents

Summary of decisions effective 1 November 2017 ........................................ 3
Section H changes to Part II ........................................................................... 5
Index ........................................................................................................... 19
Summary of decisions
EFFECTIVE 1 NOVEMBER 2017

• Allopurinol (DP-Allopurinol) tab 100 mg and 300 mg – new listing and addition of HSS

• Allopurinol (Allopurinol-Apotex) tab 100 mg and 300 mg – to be delisted 1 January 2018

• Amino acid formula (e.g. Neocate Junior Unflavoured) powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can – new listing of example brand

• Amino acid formula (Neocate Junior Vanilla) powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can – new listing

• Amino acid formula (e.g. Neocate Advance) powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can – to be delisted 1 January 2018

• Amino acid formula (Neocate Advance (Vanilla)) powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can – to be delisted 1 January 2018

• Anastrozole (Rolin) tab 1 mg – new listing and addition of HSS

• Anastrozole (Aremed and DP-Anastrozole) tab 1 mg – to be delisted 1 January 2018

• Betamethasone valerate with sodium fusidate [fusidic acid] crm 0.1% with sodium fusidate (fusidic acid) 2% - amended chemical name and presentation description

• Ceftazidime (Ceftazidime Mylan) inj 1 g vial – new listing

• Ceftazidime (Fortum) inj 500 mg, 1 g and 2 g vial – to be delisted 1 March 2018

• Cefuroxime (Cefuroxime Actavis) inj 750 mg and 1.5 g vial – new listing and addition of HSS

• Cefuroxime (Zinacef) inj 750 mg and 1.5 g vial – to be delisted 1 February 2018

• Clotrimazole (Clomazol) crm 1% – price increase and addition of HSS

• Dexamethasone (Ozurdex) ocular implant 700 mcg – new listing

• Ethinyloestradiol with levonorgestrel tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets (Microgynon 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets (Levlen ED) – new listing and addition of HSS

• Ethinyloestradiol with levonorgestrel tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets (Ava 20 ED) and tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets (Ava 30 ED) – to be delisted 1 January 2018
Summary of decisions – effective 1 November 2017 (continued)

- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Molaxole) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – new listing and addition of HSS

- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (Lax-Sachets) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – to be delisted 1 February 2018

- Metoclopramide hydrochloride (Metoclopramide Actavis 10) tab 10 mg – new listing and addition of HSS

- Metoclopramide hydrochloride (Metamide) tab 10 mg – to be delisted 1 January 2018

- Metolazone tab 5 mg – amended restriction

- Miconazole nitrate (Multichem) crm 2% – price increase and addition of HSS

- Minoxidil (Loniten) tab 10 mg – restriction removed

- Paclitaxel (Paclitaxel Ebewe) inj 6 mg per ml, 100 ml vial – to be delisted 1 April 2018

- Pemetrexed (Juno Pemetrexed) inj 100 mg and 500 mg vial – new listing

- Pyridoxine hydrochloride (Vitamin B6 25) tab 25 mg – price increase and addition of HSS

- Simvastatin (Simvastatin Mylan) tab 10 mg, 20 mg, 40 mg and 80 mg – new listing and addition of HSS

- Simvastatin (Arrow-Simva) tab 10 mg, 20 mg, 40 mg and 80 mg – to be delisted 1 January 2018

- Sodium cromoglicate cap 100 mg; nasal spray 4%; aerosol inhaler 5 mg per dose and eye drops 2% - amended chemical name

- Sodium fusidate [fusidic acid] crm 2% (DP Fusidic Acid Cream); oint 2% (Foban); tab 250 mg (Fucidin) and eye drops 1% (Fucithalmic) – amended chemical name

- Terbinafine (Deolate) tab 250 mg – new listing and addition of HSS

- Terbinafine (Dr Reddy’s Terbinafine) tab 250 mg – to be delisted 1 January 2018

- Testosterone cipionate (Depo-Testosterone) inj 100 mg per ml, 10 ml vial – amended chemical name

- Travoprost (Travopt) eye drops 0.004% – new listing and addition of HSS
Section H changes to Part II
Effective 1 November 2017

ALIMENTARY TRACT AND METABOLISM

14 SODIUM CROMOGLICATE CROMOGLYCATE (amended chemical name)
Cap 100 mg

20 MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE
(brand change)
➔ Powder for oral soln 13.125 g with potassium chloride
46.6 mg, sodium bicarbonate 178.5 mg and
sodium chloride 350.7 mg – 1% DV Feb-18 to 2020 ............ 6.78 30 Molaxole
Note – Lax-Sachets powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate
178.5 mg and sodium chloride 350.7 mg to be delisted from 1 February 2018.

27 PYRIDOXINE HYDROCHLORIDE (↑ price and addition of HSS)
Tab 25 mg – 1% DV Jan-18 to 2020................................. 2.70 90 Vitamin B6 25

CARDIOVASCULAR SYSTEM

48 METOLAZONE (amended restriction)
➔ Tab 5 mg
Restricted
Initiation
Either: Any of the following:
1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide
combination therapy; or
2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated
albumin infusions; or
3 Paediatric patient has oedema secondary to nephrotic syndrome that has not responded to loop diuretics.

49 SIMVASTATIN (brand change)
Tab 10 mg – 1% DV Jan-18 to 2020................................. 0.95 90 Simavastatin Mylan
Tab 20 mg – 1% DV Jan-18 to 2020................................. 1.52 90 Simavastatin Mylan
Tab 40 mg – 1% DV Jan-18 to 2020................................. 2.63 90 Simavastatin Mylan
Tab 80 mg – 1% DV Jan-18 to 2020................................. 6.00 90 Simavastatin Mylan
Note – Arrow-Simva tab 10 mg, 20 mg, 40 mg and 80 mg to be delisted from 1 January 2018.

52 MINOXIDIL (restriction removed)
Tab 10 mg ........................................................................ 70.00 100 Loniten
Restricted
Initiation
For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies

DERMATOLOGICALS

55 SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name)
Crm 2%................................................................. 2.52 15 g DP Fusidic Acid Cream
Oint 2%................................................................. 3.45 15 g Foban

Products with Hospital Supply Status (HSS) are in **bold**.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Changes to Section H Part II – effective 1 November 2017 (continued)

55  CLOTRIMAZOLE (1 price and addition of HSS)
    Crm 1% – 1% DV Jan-18 to 2020 ............................................. 0.70  20 g  Clomazol

55  MICONAZOLE NITRATE (1 price and addition of HSS)
    Crm 2% – 1% DV Jan-18 to 2020 ............................................. 0.74  15 g  Multichem

59  BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name and presentation)
    Crm 0.1% with sodium fusidate (fusidic acid) 2%

GENITO-URINARY SYSTEM

61  ETHINYLÖESTRADIOL WITH LEVONORGESTREL (brand change)
    Tab 20 mcg with levonorgestrel 100 mcg and
    7 inert tablets – 1% DV Jan-18 to 2020 ............................................. 2.18  84  Microgynon 20 ED
    Tab 30 mcg with levonorgestrel 150 mcg and
    7 inert tablets – 1% DV Jan-18 to 2020 ............................................. 1.77  84  Levlエン ED
    Note – Ava 20 ED tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets and Ava 30 ED tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets to be delisted from 1 January 2018.

HORMONE PREPARATIONS

66  TESTOSTERONE CIPIONATE CYPIONATE (amended chemical name)
    Inj 100 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020 ........... 76.50  1  Depo-Testosterone

INFECTIONS

77  CEFUROXIME (brand change)
    Inj 750 mg vial – 1% DV Feb-18 to 2020 .......................... 9.85  10  Cefuroxime Actavis
    Inj 1.5 g vial – 1% DV Feb-18 to 2020 .............................. 14.36  10  Cefuroxime Actavis
    Note – Zinacef inj 750 mg and 1.5 g vials to be delisted from 1 February 2018.

77  CEFTAZIDIME (brand change)
    ➔ Inj 1 g vial ...................................................... 23.00  5  Ceftazidime Mylan
    Note – Fortum inj 1 g vial to be delisted from 1 March 2018.

77  CEFTAZIDIME (delisting)
    ➔ Inj 500 mg vial .................................................. 5.30  1  Fortum
    ➔ Inj 2 g vial ....................................................... 3.34  1  Fortum
    Note – Fortum inj 500 mg and 2 g vials to be delisted from 1 March 2018.

83  SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name)
    ➔ Tab 250 mg – 1% DV Jun-17 to 2020 ............................. 34.50  12  Fucidin

86  TERBINAFINE (brand change)
    Tab 250 mg – 1% DV Jan-18 to 2020 ................................. 1.33  14  Deolate
    Note – Dr Reddy’s Terbinafine tab 250 mg to be delisted from 1 January 2018.
Changes to Section H Part II – effective 1 November 2017 (continued)

MUSCULOSKELETAL SYSTEM

104 ALLOPURINOL (brand change)
   Tab 100 mg – 1% DV Jan-18 to 2020 ........................................ 4.54 500 DP-Allopurinol
   Tab 300 mg – 1% DV Jan-18 to 2020 ...................................... 10.35 500 DP-Allopurinol
   Note – Allopurinol-Apotex tab 100 mg and 300 mg to be delisted from 1 January 2018.

NERVOUS SYSTEM

123 METOCLOPRAMIDE HYDROCHLORIDE (brand change)
   Tab 10 mg – 1% DV Jan-18 to 2020 ...................................... 1.30 100 Metoclopramide
   Note – Metamide tab 10 mg to be delisted from 1 January 2018.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

139 PEMETREXED (new listing)
   ➔ Inj 100 mg vial – 1% DV Jan-18 to 2019 ............................. 60.89 1 Juno Pemetrexed
   ➔ Inj 500 mg vial – 1% DV Jan-18 to 2019 ............................. 217.77 1 Juno Pemetrexed

Restricted
Initiation – Mesothelioma
Re-assessment required after 8 months
Both:
1 Patient has been diagnosed with mesothelioma; and
2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Continuation – Mesothelioma
Re-assessment required after 8 months
All of the following:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment; and
3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initiation – Non small cell lung cancer
Re-assessment required after 8 months
Both:
1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
2 Either:
   2.1 Both:
   2.1.1 Patient has chemotherapy-naive disease; and
   2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles, or
2.2 All of the following:
   2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
   2.2.2 Patient has not received prior funded treatment with pemetrexed; and
   2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

continued...
Changes to Section H Part II – effective 1 November 2017 (continued)

Continuation – Non small cell lung cancer

Re-assessment required after 8 months

All of the following:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

147 PACLITAXEL (delisting)

Inj 6 mg per ml, 100 ml vial .................................................... 73.06 1 Paclitaxel Ebewe

Note – Paclitaxel Ebewe inj 6 mg per ml, 100 ml vial to be delisted from 1 April 2018.

150 ANASTROZOLE (brand change)

Tab 1 mg – 1% DV Jan-18 to 2020 ........................................... 5.04 30 Rolin

Note – Aremed and DP-Anastrozole tab 1 mg to be delisted 1 January 2018.

RESPIRATORY SYSTEM AND ALLERGIES

190 SODIUM CROMOGLICATE (amended chemical name)
Nasal spray 4%

194 SODIUM CROMOGLICATE (amended chemical name)
Aerosol inhaler 5 mg per dose

SENSORY ORGANS

196 SODIUM FUSIDATE [FUSIDIC ACID] (amended chemical name)
Eye drops 1%................................................................. 4.50 5 g Fucithalmic

197 DEXAMETHASONE (new listing)

⇒ Ocular implant 700 mcg ........................................... 1,444.50 1 Ozurdex

Restricted

Initiation – Diabetic macular oedema

Ophthalmologist

Limited to 12 months treatment

1. Patients have diabetic macular oedema with pseudophakic lens; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Either:
   3.1 Patient’s disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF inhibitors; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.

Continuation – Diabetic macular oedema

Ophthalmologist

Limited to 12 months treatment

Both:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.

continued...
Changes to Section H Part II – effective 1 November 2017 (continued)

Initiation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

Limited to 12 months treatment

All of the following:

1. Patients have diabetic macular oedema; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Patient is of child bearing potential and has not yet completed a family; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.

Continuation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

Limited to 12 months treatment

All of the following:

1. Patient’s vision is stable or has improved (prescriber determined); and
2. Patient is of child bearing potential and has not yet completed a family; and
3. Dexamethasone implants are to be administered not more frequently than once every 4 months, and up to a maximum of 3 implants per year.

197 SODIUM CROMOGLICATE CROMOGLYCATE (amended chemical name)

Eye drops 2%

200 TRAVOPROST (new listing)

Eye drops 0.004% – 1% DV Jan-18 to 2020 ......................... 7.30 5 ml Travopt

SPECIAL FOODS

221 AMINO ACID FORMULA (brand change)

⇒ Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can

⇒ e.g. Neocate Junior Unflavoured

Note – Neocate Advance powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can to be delisted from 1 January 2018

221 AMINO ACID FORMULA (brand change)

⇒ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can................................................................. 53.00 400 g Neocate Junior Vanilla

Note – Neocate Advance (Vanilla) powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can to be delisted from 1 January 2018
Changes to Section H Part II – effective 1 October 2017

ALIMENTARY TRACT AND METABOLISM

14 OLSALAZINE (new listing)
   Tab 500 mg ................................................................. 93.37 100 Dipentum
   Cap 250 mg ............................................................... 53.00 100 Dipentum

15 HYOSCINE BUTYLBROMIDE (brand change)
   Tab 10 mg – 1% DV Dec-17 to 2020 ........................................... 8.75 100 Buscopan
   Note – Gastrosoothe tab 10 mg to be delisted from 1 December 2017.

26 MULTIVITAMIN RENAL (↑ price)
   ➔ Cap ................................................................. 6.49 30 Clinicians Renal Vit

CARDIOVASCULAR SYSTEM

45 BISOPROLOL FUMARATE (pack size change and addition of HSS)
   Tab 2.5 mg – 1% DV Dec-17 to 2020 .................................. 3.53 90 Bosvate
   Tab 5 mg – 1% DV Dec-17 to 2020 .................................. 5.15 90 Bosvate
   Tab 10 mg – 1% DV Dec-17 to 2020 .............................. 9.40 90 Bosvate
   Note – This is a listing of a new pack size. Bosvate tab 2.5 mg, 5 mg and 10 mg, 30 tab pack to be delisted from 1 December 2017.

45 CARVEDILOL (brand change)
   Tab 6.25 mg – 1% DV Dec-17 to 2020 ............................. 2.24 60 Carvedilol Sandoz
   Tab 12.5 mg – 1% DV Dec-17 to 2020 ............................ 2.30 60 Carvedilol Sandoz
   Tab 25 mg – 1% DV Dec-17 to 2020 .............................. 2.95 60 Carvedilol Sandoz
   Tab 50 mg – 1% DV Dec-17 to 2020 ............................. 5.24 30 Carvedilol Sandoz
   Note – Dicarz tab 6.25 mg, 12.5 mg and 25 mg to be delisted from 1 December 2017.

45 METOPROLOL SUCCINATE (brand change)
   Tab long-acting 23.75 mg – 1% DV Mar-18 to 2020 ........ 1.03 30 Betaloc CR
   Tab long-acting 47.5 mg – 1% DV Mar-18 to 2020 ........ 1.25 30 Betaloc CR
   Tab long-acting 95 mg – 1% DV Mar-18 to 2020 .......... 1.99 30 Betaloc CR
   Tab long-acting 190 mg – 1% DV Mar-18 to 2020 ...... 3.00 30 Betaloc CR
   Note – Metoprolol - AFT CR tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg to be delisted from 1 March 2018.

46 NIFEDIPINE (brand change)
   Tab long-acting 30 mg – 1% DV Dec-17 to 2020 ............ 3.14 30 Adalat Oros
   Tab long-acting 60 mg – 1% DV Dec-17 to 2020 .......... 5.67 30 Adalat Oros
   Note – Adefin XL tab long-acting 30 mg and 60 mg to be delisted 1 December 2017.

DERMATOLOGICALS

56 PERMETHRIN (↑ price and addition of HSS)
   Crm 5% – 1% DV Dec-17 to 2020 .................................. 4.95 30 g Lyderm

58 HYDROCORTISONE WITH PARAFFIN AND WOOL FAT (delisting)
   Locht 1% with paraffin liquid 15.9% and wool fat 0.6%
   Note – Hydrocortisone with paraffin and wool fat lotion 1% with paraffin liquid 15.9% and wool fat 0.6% to be delisted from 1 October 2017.
## Changes to Section H Part II – effective 1 October 2017 (continued)

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 CALCIUM GLUCONATE</td>
<td>(new listing of example brand and delisting) Gel 2.5% e.g Orion</td>
<td>$4.81</td>
<td>100 Ricit</td>
<td>Note – healthE gel 2.5% brand to be delisted from 1 April 2018.</td>
</tr>
<tr>
<td>64 FINASTERIDE</td>
<td>(brand change) ➔ Tab 5 mg – 1% DV Dec-17 to 2020</td>
<td>$1.11</td>
<td>28 Apo-Escitalopram</td>
<td>Note – Finpro tab 5 mg to be delisted from 1 December 2017.</td>
</tr>
<tr>
<td>66 TESTOSTERONE</td>
<td>(delisting) Patch 2.5 mg per day</td>
<td>$5.35</td>
<td>1,000 ml Paracare</td>
<td>Note – Androderm patch 2.5 mg per day to be delisted from 1 March 2018.</td>
</tr>
<tr>
<td>114 PARACETAMOL</td>
<td>(↑ price and addition of HSS) Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020</td>
<td>$5.35</td>
<td>1,000 ml Paracare</td>
<td></td>
</tr>
<tr>
<td>118 ESCITALOPRAM</td>
<td>(brand change) Tab 10 mg – 1% DV Dec-17 to 2020</td>
<td>$1.11</td>
<td>28 Apo-Escitalopram</td>
<td>Note – Air Flow Products tab 10 mg and 20 mg to be delisted from 1 December 2017.</td>
</tr>
<tr>
<td>120 LAMOTRIGINE</td>
<td>(delisting) Tab dispersible 25 mg</td>
<td>$14.74</td>
<td>56 Motrig</td>
<td>Note – Motrig tab dispersible 25 mg, 50 mg and 100 mg to be delisted from 1 April 2018.</td>
</tr>
<tr>
<td>126 RISPERIDONE</td>
<td>(↑ price and addition of HSS) Tab 0.5 mg – 1% DV Dec-17 to 2020</td>
<td>$1.86</td>
<td>60 Actavis</td>
<td></td>
</tr>
<tr>
<td>206 GADOBUTROL</td>
<td>(new listing) Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe</td>
<td>$120.00</td>
<td>5 Gadovist</td>
<td></td>
</tr>
</tbody>
</table>

*Products with Hospital Supply Status (HSS) are in **bold.** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
Changes to Section H Part II – effective 21 September 2017

INFECTIONS

80 AMOXICILLIN (new listing)
Grans for oral liq 250 mg per 5 ml .............................................. 1.31 100 ml Alphamox 250

Effective 1 September 2017

ALIMENTARY TRACT AND METABOLISM

18 METFORMIN HYDROCHLORIDE (delisting)
Tab immediate-release 850 mg .............................................. 7.82 500 Apotex
Note – Apotex tab immediate-release 850 mg to be delisted from 1 February 2018.

BLOOD AND BLOOD FORMING ORGANS

34 ENOXAPARIN SODIUM (↓ price)
Inj 20 mg in 0.2 ml syringe ............................................... 27.93 10 Clexane
Inj 40 mg in 0.4 ml syringe ............................................... 37.27 10 Clexane
Inj 60 mg in 0.6 ml syringe ............................................... 56.18 10 Clexane
Inj 80 mg in 0.8 ml syringe ............................................... 74.90 10 Clexane
Inj 100 mg in 1 ml syringe ............................................... 93.80 10 Clexane
Inj 120 mg in 0.8 ml syringe ........................................... 116.55 10 Clexane
Inj 150 mg in 1 ml syringe ............................................... 133.20 10 Clexane

40 SODIUM CHLORIDE (HSS suspended)
Inj 0.9%, 5 ml ampoule
– 1% DV Mar-17 to 31 Aug 2017 ........................................... 7.00 50 InterPharma

CARDIOVASCULAR SYSTEM

43 LOSARTAN POTASSIUM (↓ price and addition of HSS)
Tab 12.5 mg – 1% DV Nov-17 to 2020 ..................................... 1.39 84 Losartan Actavis
Tab 25 mg – 1% DV Nov-17 to 2020 ..................................... 1.63 84 Losartan Actavis
Tab 50 mg – 1% DV Nov-17 to 2020 ..................................... 2.00 84 Losartan Actavis
Tab 100 mg – 1% DV Nov-17 to 2020 ................................... 2.31 84 Losartan Actavis

46 PROPRANOLOL (new listing)
Tab 10 mg ................................................................. 3.65 100 Apo-Propranolol
Tab 40 mg ................................................................. 4.65 100 Apo-Propranolol
Note – This is the listing of new Pharmacodes for Apo-Propranolol tab 10 mg, 2525941 and 40 mg, 2525968.

DERMATOLOGICALS

56 ZINC AND CASTOR OIL (↓ price and addition of HSS)
Oint, BP – 1% DV Nov-17 to 2020 ..................................... 1.26 20 g healthE
Changes to Section H Part II – effective 1 September 2017 (continued)

GENITO-URINARY SYSTEM

63 ERGOMETRINE MALEATE († price and addition of HSS)
  Inj 500 mcg per ml, 1 ml ampoule
  – 1% DV Nov-17 to 2020 .................................................. 105.00  5 DBL Ergometrine

INFECTIONS

80 PIPERACILLIN WITH TAZOBACTAM (delisting)
  ➔ Inj 4 g with tazobactam 0.5 g vial................................. 5.84  1 Hospira
  Note – Hospira inj 4 g with tazobactam 0.5 g vial to be delisted from 1 January 2018.

96 OSELTAMIVIR (additional note)
  Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community
  under Rule 8 of Section H is not permitted.
  ➔ Tab 75 mg
  ➔ Powder for oral suspension 6 mg per ml

96 ZANAMIVIR (additional note)
  Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community
  under Rule 8 of Section H is not permitted.
  ➔ Powder for inhalation 5 mg ........................................ 37.38  20 dose Relenza Rotadisk

MUSCULOSKELETAL SYSTEM

99 NEOSTIGMINE METILSULFATE (addition of HSS)
  Inj 2.5 mg per ml, 1 ml ampoule
  – 1% DV Nov-17 to 2020 .................................................. 98.00  50 AstraZeneca

106 SUXAMETHONIUM CHLORIDE (addition of HSS)
  Inj 50 mg per ml, 2 ml ampoule
  – 1% DV Nov-17 to 2020 .................................................. 78.00  50 AstraZeneca

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

149 OCTREOTIDE († price, amended brand name and addition of HSS)
  Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .... 30.64  5 DBL Octreotide

149 OCTREOTIDE († price, amended brand name and addition of HSS)
  Inj 100 mcg per ml, 1 ml ampoule
  – 1% DV Nov-17 to 2020 .................................................. 18.69  5 DBL Octreotide
  Inj 500 mcg per ml, 1 ml ampoule
  – 1% DV Nov-17 to 2020 .................................................. 72.50  5 DBL Octreotide

RESPIRATORY SYSTEM AND ALLERGIES

193 FLUTICASONE († price)
  Aerosol inhaler 50 mcg per dose ....................................... 4.68  120 dose Floair
  Aerosol inhaler 125 mcg per dose ....................................... 7.22  120 dose Floair
  Aerosol inhaler 250 mcg per dose ....................................... 10.18  120 dose Floair
| 194 | SALMETEROL (↓ price) | Aerosol inhaler 25 mcg per dose | 9.90 | 120 dose | Meterol |
| 194 | FLUTICASONE WITH SALMETEROL (↓ price) | Aerosol inhaler 50 mcg with salmeterol 25 mcg | 14.58 | 120 dose | RexAir |
| 194 | | Aerosol inhaler 125 mcg with salmeterol 25 mcg | 16.83 | 120 dose | RexAir |
| 195 | AMINOPHYLLINE (↑ price and addition of HSS) | Inj 25 mg per ml, 10 ml ampoule | 124.37 | 5 | DBL Aminophylline |
| 197 | PREDNISOLONE ACETATE (HSS suspended) | Eye drops 1% – 1% DV Jan-17 to 31 Aug 2017 | 3.93 | 10 ml | Prednisolone-AFT |
| 237 | SODIUM NITROPRUSSIDE (new listing) | Test strip | 12.00 | 50 strip | Ketostix |
| 237 | SODIUM NITROPRUSSIDE (delisting) | Test strip | 6.00 | 50 strip | Accu-Chek Ketur-Test |

**Sensory Organs**

| 197 | PREDNISOLONE ACETATE (HSS suspended) | Eye drops 1% – 1% DV Jan-17 to 31 Aug 2017 | 3.93 | 10 ml | Prednisolone-AFT |

**Part III - Optional Pharmaceuticals**

| 25 | NYSTATIN (brand change) | Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020 | 1.95 | 24 ml | Nilstat |
| 27 | PYRIDOXINE HYDROCHLORIDE (↑ price and addition of HSS) | Tab 50 mg – 1% DV Oct-17 to 2020 | 13.63 | 500 | Apo-Pyridoxine |
| 27 | COLECALCIFEROL (↓ price and addition of HSS) | Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020 | 2.50 | 12 | Vit.D3 |
Changes to Section H Part II – effective 1 August 2017 (continued)

### BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>No.</th>
<th>Product</th>
<th>Brand</th>
<th>Price (ex man. Excl. GST)</th>
<th>Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>TRISODIUM CITRATE CITRATE SODIUM (amended chemical name and presentation)</td>
<td>Biomed</td>
<td>$ 5</td>
<td>Biomed</td>
</tr>
<tr>
<td></td>
<td>Inj 4% (200 mg per 5 ml), 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 46.7% (1.4 g per 3 ml), 3 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>GLUCOSE [DEXTROSE] (addition of HSS)</td>
<td>Biomed</td>
<td>$ 5</td>
<td>Biomed</td>
</tr>
<tr>
<td></td>
<td>Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020 (↑ price)</td>
<td></td>
<td>29.50</td>
<td>Biomed</td>
</tr>
<tr>
<td></td>
<td>Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020</td>
<td></td>
<td>14.50</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

### CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>No.</th>
<th>Product</th>
<th>Brand</th>
<th>Price (ex man. Excl. GST)</th>
<th>Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>BISOPROLOL FUMARATE (↑ price)</td>
<td>Bosvate</td>
<td>$ 30</td>
<td>Bosvate</td>
</tr>
<tr>
<td></td>
<td>Tab 2.5 mg</td>
<td></td>
<td>1.18</td>
<td>Bosvate</td>
</tr>
<tr>
<td></td>
<td>Tab 5 mg</td>
<td></td>
<td>1.72</td>
<td>Bosvate</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg</td>
<td></td>
<td>3.13</td>
<td>Bosvate</td>
</tr>
<tr>
<td>50</td>
<td>NICOTINIC ACID (↑ price and addition of HSS)</td>
<td>Apo-Nicotinic Acid</td>
<td>$ 100</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg – 1% DV Oct-17 to 2020</td>
<td></td>
<td>4.12</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td></td>
<td>Tab 500 mg – 1% DV Oct-17 to 2020</td>
<td></td>
<td>17.89</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td>50</td>
<td>ISOSORBIDE MONONITRATE (↑ price and addition of HSS)</td>
<td>Ismo-20</td>
<td>$ 100</td>
<td>Ismo-20</td>
</tr>
<tr>
<td></td>
<td>Tab 20 mg – 1% DV Oct-17 to 2020</td>
<td></td>
<td>18.80</td>
<td>Ismo-20</td>
</tr>
</tbody>
</table>

### DERMATOLOGICALS

<table>
<thead>
<tr>
<th>No.</th>
<th>Product</th>
<th>Brand</th>
<th>Price (ex man. Excl. GST)</th>
<th>Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>SULPHADIAZINE SILVER SULFADIAZINE SILVER (amended chemical name)</td>
<td>Flamazine</td>
<td>$ 50 g</td>
<td>Flamazine</td>
</tr>
<tr>
<td></td>
<td>Crm 1% – 1% DV Aug-17 to 2020</td>
<td></td>
<td>10.80</td>
<td>Flamazine</td>
</tr>
<tr>
<td>56</td>
<td>PERMETHRIN (↑ price and addition of HSS)</td>
<td>A-Scabies</td>
<td>$ 30 ml</td>
<td>A-Scabies</td>
</tr>
<tr>
<td></td>
<td>Lotn 5% – 1% DV Oct-17 to 2020</td>
<td></td>
<td>3.69</td>
<td>A-Scabies</td>
</tr>
<tr>
<td>57</td>
<td>EMULSIFYING OINTMENT (addition of HSS)</td>
<td>Jaychem</td>
<td>$ 100 g</td>
<td>Jaychem</td>
</tr>
<tr>
<td></td>
<td>Oint BP – 1% DV Oct-17 to 2020</td>
<td></td>
<td>1.84</td>
<td>Jaychem</td>
</tr>
<tr>
<td></td>
<td>Oint BP, 500 g – 1% DV Oct-17 to 2020 (↑ price)</td>
<td></td>
<td>3.59</td>
<td>AFT</td>
</tr>
<tr>
<td></td>
<td>Oint BP, 500 g</td>
<td>Note: DV limit applies to pack sizes of less than 200 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Note: DV limit applies to pack sizes of greater than 200 g.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN (↑ price and addition of HSS)</td>
<td>Pinetarsol</td>
<td>$ 500 ml</td>
<td>Pinetarsol</td>
</tr>
<tr>
<td></td>
<td>Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020</td>
<td></td>
<td>3.86</td>
<td>Pinetarsol</td>
</tr>
<tr>
<td></td>
<td>Note – Pinetarsol soln 2.3% with trolamine laurilsulfate and fluorescein, 1,000 ml pack to be delisted from 1 October 2017.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>No.</th>
<th>Product</th>
<th>Brand</th>
<th>Price (ex man. Excl. GST)</th>
<th>Generic</th>
</tr>
</thead>
<tbody>
<tr>
<td>63</td>
<td>OESTRIOL (new listing and addition of HSS)</td>
<td>Ovestin</td>
<td>$ 15 g</td>
<td>Ovestin</td>
</tr>
<tr>
<td></td>
<td>Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020</td>
<td></td>
<td>6.62</td>
<td>Ovestin</td>
</tr>
<tr>
<td></td>
<td>Pessaries 500 mcg – 1% DV Oct-17 to 2020</td>
<td></td>
<td>6.86</td>
<td>Ovestin</td>
</tr>
</tbody>
</table>

Note: DV limit applies to pack sizes of less than 200 g.

Note – Pinetarsol soln 2.3% with trolamine laurilsulfate and fluorescein, 1,000 ml pack to be delisted from 1 October 2017.
Changes to Section H Part II – effective 1 August 2017 (continued)

HORMONE PREPARATIONS

67  DEXAMETHASONE PHOSPHATE (delisting)
    Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019............. 12.59  5  Max Health
    Note – Max Health inj 4 mg per ml, 2 ml ampoule, 5 inj pack to be delisted from 1 September 2017. The 10 inj
    pack size remains listed.

75  DESMOPRESSIN ACETATE († price and addition of HSS)
    Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020............ 23.95  6 ml  Desmopressin-PH&T

INFECTIONS

79  CLARITHROMYCIN (new listing)
    ➔ Inj 500 mg vial................................................................. 12.04  1  Klacid

79  CLARITHROMYCIN (HSS delayed and † price)
    ➔ Inj 500 mg vial—1% DV Sep-17 to 2020.............................. 12.04  1  Martindale

80  AMOXICILLIN WITH CLAVULANIC ACID († price and addition of HSS)
    Tab 500 mg with clavulanic acid 125 mg
    – 1% DV Oct-17 to 2020............................................. 1.88  20  Augmentin

82  AZTREONAM († price)
    ➔ Inj 1 g vial................................................................. 182.46  5  Azactam

83  TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] († price and addition of HSS)
    Oral liq 8 mg with sulphamethoxazole
    40 mg per ml – 1% DV Oct-17 to 2020........................................ 2.97  100 ml  Deprim

97  PEGYLATED INTERFERON ALFA-2A († price and addition of HSS)
    ➔ Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020............500.00  4  Pegasys

97  PEGYLATED INTERFERON ALFA-2A (delisting delayed)
    ➔ Inj 180 mcg prefilled syringe (4)
        with ribavirin tab 200 mg (112)........................................... 1,169.84  1  Pegasys RBV
        Combination Pack
    Note – Pegasys RBV Combination Pack inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) delist
    delayed until further notice.

MUSCULOSKELETAL SYSTEM

107  CELECOXIB (amended restriction)
    Note – The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.
    Cap 100 mg – 1% DV Aug-17 to 2020........................................... 3.63  60  Celecoxib Pfizer
    Cap 200 mg – 1% DV Aug-17 to 2020........................................... 2.30  30  Celecoxib Pfizer

    Restricted
    Initiation
    For preoperative and/or postoperative use for a total of up to 8 days’ use.
Changes to Section H Part II – effective 1 August 2017 (continued)

107  ETORICOXIB (amended restriction)

- Tab 30 mg
- Tab 60 mg
- Tab 90 mg
- Tab 120 mg

Restricted
Initiation

For preoperative and/or postoperative use for a total of up to 8 days’ use.
For in-vivo investigation of allergy only.

108  NAPROXEN (delisting)

Tab long-acting 750 mg – 1% DV Jun-15 to 2018 ............................................. 18.00 90 Naprosyn SR 750
Tab long-acting 1 g – 1% DV Jun-15 to 2018 ............................................. 21.00 90 Naprosyn SR 1000

Note – Naprosyn SR 750 tab long-acting 750 mg and Naprosyn SR 1000 tab long-acting 1 g, 90 tab pack to be delisted from 1 October 2017. The 28 tab pack remains listed.

NERVOUS SYSTEM

112  LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change and amended presentation description)

Oral (viscous gel) soln 2% – 1% DV Oct-17 to 2020 ............................................. 38.00 200 ml Mucosoothe

Note – Xylocaine Viscous oral (gel) soln 2% to be delisted from 1 October 2017.

114  FENTANYL (addition of HSS)

Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020 († price) ........ 2.95 5 Fentanyl Sandoz
Patch 25 mcg per hour – 1% DV Oct-17 to 2020 ............................................. 3.66 5 Fentanyl Sandoz
Patch 50 mcg per hour – 1% DV Oct-17 to 2020 († price) ............. 6.65 5 Fentanyl Sandoz
Patch 75 mcg per hour – 1% DV Oct-17 to 2020 († price) ............. 9.25 5 Fentanyl Sandoz
Patch 100 mcg per hour – 1% DV Oct-17 to 2020 († price) ......... 11.40 5 Fentanyl Sandoz

115  MORPHINE SULPHATE (pack size change and addition of HSS)

Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020 ............................................. 97.25 5 Biomed
Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020 ......................... 24.00 5 Biomed
Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020 ......................... 50.75 5 Biomed

Note – Biomed inj 1 mg per ml, 100 ml bag, 1 mg per ml, 10 ml syringe and 1 mg per ml, 50 ml syringe, 10 inj pack to be delisted from 1 October 2017.

116  REMIFENTANIL HYDROCHLORIDE (brand change and amended chemical name)

Inj 1 mg vial – 1% DV Oct-17 to 2020 ............................................................... 13.95 5 Remifentanil-AFT
Inj 2 mg vial – 1% DV Oct-17 to 2020 ............................................................. 19.95 5 Remifentanil-AFT

Note – Ultiva inj 1 mg and 2 mg vial to be delisted from 1 October 2017.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

144  IMATINIB MESILATE († price and addition of HSS)

Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule

Cap 100 mg – 1% DV Oct-17 to 2020 .............................................................. 98.00 60 Imatinib-AFT
Cap 400 mg – 1% DV Oct-17 to 2020 .............................................................. 197.50 30 Imatinib-AFT

Products with Hospital Supply Status (HSS) are in **bold**.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Changes to Section H Part II – effective 1 August 2017 (continued)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
<th>Per Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>147</td>
<td>PACLITAXEL († price and addition of HSS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020</td>
<td>47.30</td>
<td>5</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020</td>
<td>20.00</td>
<td>1</td>
<td>Paclitaxel Ebewe</td>
</tr>
</tbody>
</table>

**RESPIRATORY SYSTEM AND ALLERGIES**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
<th>Per Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>190</td>
<td>IPRATROPIUM BROMIDE († price and addition of HSS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.03% – 1% DV Oct-17 to 2020</td>
<td>4.61</td>
<td>15 ml</td>
<td>Univent</td>
</tr>
</tbody>
</table>

**Effective 1 July 2017**

**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Price (ex man. Excl. GST)</th>
<th>Brand or Generic</th>
<th>Per Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>116</td>
<td>MORPHINE SULPHATE (Pharmacode change)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab immediate-release 10 mg – 1% DV Sep-17 to 2020</td>
<td>2.80</td>
<td>10</td>
<td>Sevredol</td>
</tr>
<tr>
<td></td>
<td>Tab immediate-release 20 mg – 1% DV Sep-17 to 2020</td>
<td>5.52</td>
<td>10</td>
<td>Sevredol</td>
</tr>
</tbody>
</table>

Note – this is a change from a bottle to blister pack (2520990 and 2521008 respectively). The bottle packs are to be delisted 1 October 2017.

— Restriction

(Brand) indicates a brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Index</th>
<th>Pharmaceuticals and brands</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
<td></td>
</tr>
<tr>
<td>Accu-Chek Ketur-Test ..........................</td>
<td>14</td>
</tr>
<tr>
<td>Adalat Oros ....................................</td>
<td>10</td>
</tr>
<tr>
<td>Alloprimin .......................................</td>
<td>7</td>
</tr>
<tr>
<td>Alphamox 125 ....................................</td>
<td>12</td>
</tr>
<tr>
<td>Amino acid formula ............................</td>
<td>9</td>
</tr>
<tr>
<td>Aminophylline ...................................</td>
<td>14</td>
</tr>
<tr>
<td>Amoxicillin .....................................</td>
<td>12</td>
</tr>
<tr>
<td>Amoxicillin with clavulanic acid ............</td>
<td>16</td>
</tr>
<tr>
<td>Anastrozole ....................................</td>
<td>8</td>
</tr>
<tr>
<td>Androderm .......................................</td>
<td>11</td>
</tr>
<tr>
<td>Apo-Escitalopram ................................</td>
<td>11</td>
</tr>
<tr>
<td>Apo-Nicotinic Acid .............................</td>
<td>15</td>
</tr>
<tr>
<td>Apo-Propranolol ..................................</td>
<td>12</td>
</tr>
<tr>
<td>Apo-Pyridoxine ..................................</td>
<td>14</td>
</tr>
<tr>
<td>A-Scabies .......................................</td>
<td>15</td>
</tr>
<tr>
<td>Augmentin .......................................</td>
<td>16</td>
</tr>
<tr>
<td>Azactam .........................................</td>
<td>16</td>
</tr>
<tr>
<td>Aztreonam ........................................</td>
<td>16</td>
</tr>
<tr>
<td><strong>B</strong></td>
<td></td>
</tr>
<tr>
<td>Betaloc CR ......................................</td>
<td>10</td>
</tr>
<tr>
<td>Betamethasone valerate with fusidic acid ....</td>
<td>6</td>
</tr>
<tr>
<td>Betamethasone valerate with sodium fusidate</td>
<td>6</td>
</tr>
<tr>
<td>[fusidic acid] ..................................</td>
<td>6</td>
</tr>
<tr>
<td>Bisoprolol fumarate ...........................</td>
<td>10, 15</td>
</tr>
<tr>
<td>Bosvate .........................................</td>
<td>10, 15</td>
</tr>
<tr>
<td>Buscopan ........................................</td>
<td>10</td>
</tr>
<tr>
<td><strong>C</strong></td>
<td></td>
</tr>
<tr>
<td>Calcium gluconate ................................</td>
<td>11</td>
</tr>
<tr>
<td>Carvedilol ......................................</td>
<td>10</td>
</tr>
<tr>
<td>Carvedilol Sandoz ................................</td>
<td>10</td>
</tr>
<tr>
<td>Ceftazidime .....................................</td>
<td>6</td>
</tr>
<tr>
<td>Ceftazidime Mylan ................................</td>
<td>6</td>
</tr>
<tr>
<td>Cefuroxime ......................................</td>
<td>6</td>
</tr>
<tr>
<td>Cefuroxime Actavis ................................</td>
<td>6</td>
</tr>
<tr>
<td>Celecoxib .......................................</td>
<td>16</td>
</tr>
<tr>
<td>Celecoxib Pfizer ..................................</td>
<td>16</td>
</tr>
<tr>
<td>Citrate sodium ...................................</td>
<td>15</td>
</tr>
<tr>
<td>Clarithromycin ...................................</td>
<td>16</td>
</tr>
<tr>
<td>Cleane ..........................................</td>
<td>12</td>
</tr>
<tr>
<td>Clinicians Renal Vit. ..........................</td>
<td>10</td>
</tr>
<tr>
<td>Clomazol ........................................</td>
<td>6</td>
</tr>
<tr>
<td>Clotrimazole .....................................</td>
<td>6</td>
</tr>
<tr>
<td>Colecalciferol ...................................</td>
<td>14</td>
</tr>
<tr>
<td>Co-trimoxazole .................................</td>
<td>16</td>
</tr>
<tr>
<td><strong>D</strong></td>
<td></td>
</tr>
<tr>
<td>DBL Aminophylline ................................</td>
<td>14</td>
</tr>
<tr>
<td>DBL Ergometrine ..................................</td>
<td>13</td>
</tr>
<tr>
<td>DBL Octreotide ...................................</td>
<td>13</td>
</tr>
<tr>
<td>Deolate ..........................................</td>
<td>6</td>
</tr>
<tr>
<td>Depo-Testosterone ................................</td>
<td>6</td>
</tr>
<tr>
<td>Deprim ............................................</td>
<td>16</td>
</tr>
<tr>
<td>Desmopressin acetate ...........................</td>
<td>16</td>
</tr>
<tr>
<td>Desmopressin-PH&amp;T ................................</td>
<td>16</td>
</tr>
<tr>
<td>Dexamethasone ...................................</td>
<td>8</td>
</tr>
<tr>
<td>Dexamethasone phosphate .......................</td>
<td>16</td>
</tr>
<tr>
<td>Dextrose .........................................</td>
<td>15</td>
</tr>
<tr>
<td>Dipentum .........................................</td>
<td>10</td>
</tr>
<tr>
<td>DP-Allopurinol ...................................</td>
<td>7</td>
</tr>
<tr>
<td>DP Fusidic Acid Cream ................................</td>
<td>5</td>
</tr>
<tr>
<td><strong>E</strong></td>
<td></td>
</tr>
<tr>
<td>Emulsifying ointment .........................</td>
<td>15</td>
</tr>
<tr>
<td>Enoxaparin sodium ..............................</td>
<td>12</td>
</tr>
<tr>
<td>Ergometrine maleate ............................</td>
<td>13</td>
</tr>
<tr>
<td>Escitalopram ....................................</td>
<td>11</td>
</tr>
<tr>
<td>Ethynylestradiol with levonorgestrel ..........</td>
<td>6</td>
</tr>
<tr>
<td>Etoricoxib .......................................</td>
<td>17</td>
</tr>
<tr>
<td><strong>F</strong></td>
<td></td>
</tr>
<tr>
<td>Fentanyl .........................................</td>
<td>17</td>
</tr>
<tr>
<td>Fentanyl Sandoz ..................................</td>
<td>17</td>
</tr>
<tr>
<td>Finasteride .....................................</td>
<td>11</td>
</tr>
<tr>
<td>Flavamine .......................................</td>
<td>15</td>
</tr>
<tr>
<td>Floam ............................................</td>
<td>13</td>
</tr>
<tr>
<td>Fluticasone .....................................</td>
<td>13</td>
</tr>
<tr>
<td>Fluticasone with salmeterol .................</td>
<td>14</td>
</tr>
<tr>
<td>Foban ............................................</td>
<td>5</td>
</tr>
<tr>
<td>Fortum ..........................................</td>
<td>6</td>
</tr>
<tr>
<td>Fucidin .........................................</td>
<td>6</td>
</tr>
<tr>
<td>Fucithalmic .....................................</td>
<td>8</td>
</tr>
<tr>
<td>Fusidic acid ....................................</td>
<td>5, 6, 8</td>
</tr>
<tr>
<td><strong>G</strong></td>
<td></td>
</tr>
<tr>
<td>Gadobutrol .....................................</td>
<td>11</td>
</tr>
<tr>
<td>Gadovist .......................................</td>
<td>11</td>
</tr>
<tr>
<td>Glucose [dextrose] ..............................</td>
<td>15</td>
</tr>
<tr>
<td><strong>H</strong></td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone with paraffin and wool fat ...</td>
<td>10</td>
</tr>
<tr>
<td>Hyoscine butylbromide .........................</td>
<td>10</td>
</tr>
<tr>
<td><strong>I</strong></td>
<td></td>
</tr>
<tr>
<td>Imatinib-AFT ....................................</td>
<td>17</td>
</tr>
<tr>
<td>Imatinib mesilate ................................</td>
<td>17</td>
</tr>
<tr>
<td>Ipratropium bromide ............................</td>
<td>18</td>
</tr>
<tr>
<td>Ismo-20 ..........................................</td>
<td>15</td>
</tr>
<tr>
<td>Isosorbide mononitrate ........................</td>
<td>15</td>
</tr>
<tr>
<td>Ispaghula (psyllium) husk ......................</td>
<td>14</td>
</tr>
<tr>
<td><strong>J</strong></td>
<td></td>
</tr>
<tr>
<td>Juno Pemetrexed ..................................</td>
<td>7</td>
</tr>
<tr>
<td><strong>K</strong></td>
<td></td>
</tr>
<tr>
<td>Ketostix ........................................</td>
<td>14</td>
</tr>
<tr>
<td>Klacid ..........................................</td>
<td>16</td>
</tr>
<tr>
<td>Konsyl-D .......................................</td>
<td>14</td>
</tr>
<tr>
<td><strong>L</strong></td>
<td></td>
</tr>
<tr>
<td>Lamotrigine ....................................</td>
<td>11</td>
</tr>
</tbody>
</table>
# Index

**Pharmaceuticals and brands**

<table>
<thead>
<tr>
<th>Brand/Drug</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levlen ED</td>
<td>6</td>
</tr>
<tr>
<td>Lidocaine [lignocaine] hydrochloride</td>
<td>17</td>
</tr>
<tr>
<td>Lignocaine</td>
<td>17</td>
</tr>
<tr>
<td>Loniten</td>
<td>5</td>
</tr>
<tr>
<td>Losartan Actavis</td>
<td>12</td>
</tr>
<tr>
<td>Losartan potassium</td>
<td>10</td>
</tr>
<tr>
<td>Lyderm</td>
<td>10</td>
</tr>
<tr>
<td>Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride</td>
<td>5</td>
</tr>
<tr>
<td>Meterol</td>
<td>14</td>
</tr>
<tr>
<td>Metformin hydrochloride</td>
<td>12</td>
</tr>
<tr>
<td>Metoclopramide Actavis</td>
<td>7</td>
</tr>
<tr>
<td>Metoclopramide hydrochloride</td>
<td>7</td>
</tr>
<tr>
<td>Metolazone</td>
<td>5</td>
</tr>
<tr>
<td>Metoprolol succinate</td>
<td>10</td>
</tr>
<tr>
<td>Miconazole nitrate</td>
<td>6</td>
</tr>
<tr>
<td>Micracyon 20 ED</td>
<td>6</td>
</tr>
<tr>
<td>Minoxidil</td>
<td>5</td>
</tr>
<tr>
<td>Moloxol</td>
<td>5</td>
</tr>
<tr>
<td>Morphine sulphate</td>
<td>17, 18</td>
</tr>
<tr>
<td>Motrig</td>
<td>11</td>
</tr>
<tr>
<td>Mucosothe</td>
<td>17</td>
</tr>
<tr>
<td>Multivitamin renal</td>
<td>10</td>
</tr>
<tr>
<td>Naprosyn SR 750</td>
<td>17</td>
</tr>
<tr>
<td>Naprosyn SR 1000</td>
<td>17</td>
</tr>
<tr>
<td>Naproxen</td>
<td>17</td>
</tr>
<tr>
<td>Neocate Junior Unflavoured</td>
<td>9</td>
</tr>
<tr>
<td>Neocate Junior Vanilla</td>
<td>9</td>
</tr>
<tr>
<td>Neostigmine metilsulfate</td>
<td>13</td>
</tr>
<tr>
<td>Nicotinic acid</td>
<td>15</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>10</td>
</tr>
<tr>
<td>Nilstat</td>
<td>14</td>
</tr>
<tr>
<td>Nystatin</td>
<td>14</td>
</tr>
<tr>
<td>Octreotide</td>
<td>13</td>
</tr>
<tr>
<td>Oestriol</td>
<td>15</td>
</tr>
<tr>
<td>Olsalazine</td>
<td>10</td>
</tr>
<tr>
<td>Oseltamivir</td>
<td>13</td>
</tr>
<tr>
<td>Ovestin</td>
<td>15</td>
</tr>
<tr>
<td>Ozurdex</td>
<td>8</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>8, 18</td>
</tr>
<tr>
<td>Paclitaxel Ebewe</td>
<td>8, 18</td>
</tr>
<tr>
<td>Paracare</td>
<td>11</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>11</td>
</tr>
<tr>
<td>Pegasys</td>
<td>16</td>
</tr>
<tr>
<td>Pegasys RBV Combination Pack</td>
<td>16</td>
</tr>
<tr>
<td>Pegylated interferon alfa-2A</td>
<td>16</td>
</tr>
<tr>
<td>Pemtirexed</td>
<td>7</td>
</tr>
<tr>
<td>Peptisoothe</td>
<td>14</td>
</tr>
<tr>
<td>Permethrin</td>
<td>10, 15</td>
</tr>
<tr>
<td>Pinetasol</td>
<td>15</td>
</tr>
<tr>
<td>Pine tar with trolamine laurilsulfate and fluorescein</td>
<td>15</td>
</tr>
<tr>
<td>Piperacillin with tazobactam</td>
<td>13</td>
</tr>
<tr>
<td>Prednisolone acetate</td>
<td>14</td>
</tr>
<tr>
<td>Prednisolone-AFT</td>
<td>14</td>
</tr>
<tr>
<td>Propranolol</td>
<td>12</td>
</tr>
<tr>
<td>Pyridoxine hydrochloride</td>
<td>5, 14</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>14</td>
</tr>
<tr>
<td>Ranitidine Relief</td>
<td>14</td>
</tr>
<tr>
<td>Relenza Rotadisk</td>
<td>13</td>
</tr>
<tr>
<td>Remifentanil</td>
<td>17</td>
</tr>
<tr>
<td>Remifentanil-AFT</td>
<td>17</td>
</tr>
<tr>
<td>Remifentanil hydrochloride</td>
<td>17</td>
</tr>
<tr>
<td>RexAir</td>
<td>14</td>
</tr>
<tr>
<td>Ricil</td>
<td>11</td>
</tr>
<tr>
<td>Risperidone</td>
<td>11</td>
</tr>
<tr>
<td>Rolin</td>
<td>8</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>14</td>
</tr>
<tr>
<td>Sevredol</td>
<td>18</td>
</tr>
<tr>
<td>Simavastatin Mylan</td>
<td>5</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>5</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>12</td>
</tr>
<tr>
<td>Sodium cromoglicate</td>
<td>5, 8, 9</td>
</tr>
<tr>
<td>Sodium cromoglycate</td>
<td>5, 8, 9</td>
</tr>
<tr>
<td>Sodium fusidate [fusidic acid]</td>
<td>5, 6, 8</td>
</tr>
<tr>
<td>Sodium nitroprusside</td>
<td>14</td>
</tr>
<tr>
<td>Sulfadiazine silver</td>
<td>15</td>
</tr>
<tr>
<td>Sulphadiazine silver</td>
<td>15</td>
</tr>
<tr>
<td>Suxamethonium chloride</td>
<td>13</td>
</tr>
<tr>
<td>Terbinafine</td>
<td>6</td>
</tr>
<tr>
<td>Testosterone</td>
<td>11</td>
</tr>
<tr>
<td>Testosterone cipionate</td>
<td>6</td>
</tr>
<tr>
<td>Testosterone cypionate</td>
<td>6</td>
</tr>
<tr>
<td>Travoprost</td>
<td>9</td>
</tr>
<tr>
<td>Travopt</td>
<td>9</td>
</tr>
<tr>
<td>Trimethoprim with sulphamethoxazole</td>
<td>16</td>
</tr>
<tr>
<td>[co-trimoxazole]</td>
<td>16</td>
</tr>
<tr>
<td>Trisodium citrate</td>
<td>15</td>
</tr>
<tr>
<td>Univent</td>
<td>18</td>
</tr>
<tr>
<td>Vitamin B6 25</td>
<td>5</td>
</tr>
<tr>
<td>Vit.D3</td>
<td>14</td>
</tr>
<tr>
<td>Zanamivir</td>
<td>13</td>
</tr>
<tr>
<td>Zinc and castor oil</td>
<td>12</td>
</tr>
</tbody>
</table>